Circulating 25-Hydroxyvitamin D and Risk of Kidney Cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers by Gallicchio, Lisa et al.
American Journal of Epidemiology
ª The Author 2010. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Vol. 172, No. 1
DOI: 10.1093/aje/kwq115
Advance Access publication:
June 18, 2010
Original Contribution
Circulating 25-Hydroxyvitamin D and Risk of Kidney Cancer
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Lisa Gallicchio*, Lee E. Moore, Victoria L. Stevens, Jiyoung Ahn, Demetrius Albanes,
Virginia Hartmuller, V. Wendy Setiawan, Kathy J. Helzlsouer, Gong Yang, Yong-Bing Xiang,
Xiao-Ou Shu, Kirk Snyder, Stephanie J. Weinstein, Kai Yu, Anne Zeleniuch-Jacquotte, Wei Zheng,
Qiuyin Cai, David S. Campbell, Yu Chen, Wong-Ho Chow, Ronald L. Horst, Laurence N. Kolonel,
Marjorie L. McCullough, Mark P. Purdue, and Karen L. Koenig
* Correspondence to Dr. Lisa Gallicchio, The Prevention and Research Center, The Weinberg Center for Women’s Health and
Medicine, Mercy Medical Center, 227 St. Paul Place, 6th Floor, Baltimore, MD 21202 (e-mail: lgallic@mdmercy.com).
Initially submitted October 23, 2009; accepted for publication April 12, 2010.
Although the kidney is a major organ for vitamin D metabolism, activity, and calcium-related homeostasis, little is
known about whether this nutrient plays a role in the development or the inhibition of kidney cancer. To address this
gap in knowledge, the authors examined the association between circulating 25-hydroxyvitamin D (25(OH)D) and
kidney cancer within a large, nested case-control study developed as part of the Cohort Consortium Vitamin D
Pooling Project of Rarer Cancers. Concentrations of 25(OH)D were measured from 775 kidney cancer cases and
775 age-, sex-, race-, and season-matched controls from 8 prospective cohort studies. Overall, neither low nor high
concentrations of circulating 25(OH)D were signiﬁcantly associated with kidney cancer risk. Although the data
showed a statistically signiﬁcant decreased risk for females (odds ratio ¼ 0.31, 95% conﬁdence interval: 0.12, 0.85)
with 25(OH)D concentrations of  75 nmol/L, the linear trend was not statistically signiﬁcant and the number of
cases in this category was small (n ¼ 14). The ﬁndings from this consortium-based study do not support the
hypothesis that vitamin D is inversely associated with the risk of kidney cancer overall or with renal cell carcinoma
speciﬁcally.
case-control studies; cohort studies; kidney neoplasms; prospective studies; vitamin D
Abbreviations: CI, conﬁdence interval; ICD-8 (9), International Classiﬁcation of Diseases, Eighth (Ninth) Revision; ICD-10:
International Statistical Classiﬁcation of Diseases and Related Health Problems, Tenth Revision; ICD-O, International Classiﬁca-
tion of Diseases for Oncology; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio; VDPP, Cohort Consortium Vitamin D Pooling
Project of Rarer Cancers.
In the United States, kidney cancer incidence has been
increasing at a rate of approximately 2% per year and ac-
counts for 2.6% of all newly diagnosed cancer cases (1).
Renal cell carcinoma is the most common type of kidney
cancer, and incidence rates of this histologic type are twice
as high among males compared with females (2). The estab-
lished risk factors for renal cell carcinoma are cigarette
smoking, hypertension, and obesity (3).
Recent widespread interest has focused on the health-
promoting effects of vitamin D, the ‘‘sunshine’’ vitamin.
Vitamin D is well known for its role in promoting bone
health through the regulation of bone growth and remodel-
ing as well as calcium homeostasis (4). In addition, there is
increasing laboratory evidence that vitamin D is an
anticarcinogenic agent (4, 5). Vitamin D is obtained from
exposure to ultraviolet light (sunlight) and certain foods such
as oily ﬁsh and vitamin-D-fortiﬁed milk, orange juice, and
cereal. It is metabolized to 25-hydroxyvitamin D (25(OH)D),
the accepted biomarker of vitamin D status (6), which is
activated to 1,25 dihydroxyvitamin D in the kidney. This
47 Am J Epidemiol 2010;172:47–57metabolite in turn regulates the expression of many proteins
involved in cellular proliferation, differentiation, and apopto-
sis (7).
Studies indicate that vitamin D, measured as circulating
25(OH)D, may be associated with a reduced risk of several
types of cancer, including colon, breast, and prostate (8–11).
Although the kidney is a major organ for vitamin D metab-
olism and activity, and related calcium homeostasis, little is
known about the association between vitamin D and cancer
in this organ. Ecologic studies conducted in the United
States and globally have shown an inverse association
between levels of solar ultraviolet irradiance and kidney
cancer incidence (12, 13). In contrast, 2 prospective cohort
and 2 case-control studies focusing on dietary vitamin D
reported no statistically signiﬁcant association with the de-
velopment of kidney cancer (14–17). However, the rele-
vance of these studies is limited by study design issues
(14, 16), a small number of cases (15), and the absence of
data on vitamin D from ultraviolet light exposure (14–17),
the principal source of circulating vitamin D.
In this study, the association between circulating
25(OH)D and kidney cancer was examined within a large,
nested case-control study developed as part of the Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers
(VDPP). For this investigation, prediagnostic 25(OH)D con-
centrations were measured and data were analyzed from 775
kidney cancer cases and 775 controls participating in 8 pro-
spective cohorts.
MATERIALS AND METHODS
A detailed description of cohorts participating in VDPP
and the general methods for the project are provided in
a separate paper (18). Of the 10 cohorts in VDPP, the fol-
lowing 8 contributed cases of kidney cancer: the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study
(ATBC); the Cancer Prevention Study II Nutrition Cohort
(CPS-II); CLUE; the Multiethnic Cohort Study (MEC); the
New York University Women’s Health Study (NYU-WHS);
the Prostate, Lung, Colorectal and Ovarian Cancer Screen-
ing Trial (PLCO); the Shanghai Men’s Health Study
(SMHS); and the Shanghai Women’s Health Study (SWHS).
From these 8 cohorts, plasma/serum samples from 783
kidney cancer cases and 783 controls, alive and not diag-
nosed with cancer at the time of case diagnosis, and matched
on age at blood collection (61 year), sex, race (white/black/
Asian/other), and date of blood draw (630 days), were sent
to the laboratory for measurement of circulating 25(OH)D.
Five cases were excluded after 25(OH)D measurement
because they were found to have cancer of the ureter
(International Classiﬁcation of Diseases, Eighth Revision
(ICD-8)/International Classiﬁcation of Diseases, Ninth Re-
vision (ICD-9) code 189.2 or International Statistical Clas-
siﬁcation of Diseases and Related Health Problems, Tenth
Revision (ICD-10) code C66 or International Classiﬁcation
of Diseases for Oncology (ICD-O) code C66.9) or cancer of
a urinary organ, site unspeciﬁed (ICD-8/ICD-9 code 189.9
or ICD-10 code C68 or ICD-O code C68–C68.9). Further-
more, 2 cases were excluded after 25(OH)D measurement
because their date of diagnosis was prior to their date of
blood draw, and 1 control was excluded because no
25(OH)D data were returned from the laboratory. The re-
maining 776 cases and 782 controls were eligible to be in-
cluded in the analytic data set. Because only matched pairs
were analyzed, the ﬁnal analytic data set consisted of 775
matched case-control pairs. Cases included 708 with renal
cell carcinoma (ICD-8/ICD-9 code 189.0 or ICD-10 code
C64 or ICD-O code 64.9) and 67 with carcinoma of the renal
pelvis (ICD-8/ICD-9 code 189.1 or ICD-9/ICD-10 code C65
or ICD-O code 65.9).
All serum/plasma samples were measured for 25(OH)D
at Heartland Assays, Inc., as described in Gallicchio et al.
(18). The quality control measures included use of samples
of the vitamin D standard from the National Institute of
Standards and Technology (NIST) at both a ‘‘normal’’
(~65 nmol/L) and a ‘‘low’’ (~35 nmol/L) level. As reported
in Gallicchio et al. (18) for the VDPP, interbatch and intra-
batch coefﬁcients of variation for low-level samples were
12.7% and 9.3%, respectively; interbatch and intrabatch co-
efﬁcients of variation for normal-level samples were 13.6%
and 11.0%, respectively. The median interbatch coefﬁcient
of variation for the cohort quality control samples was
13.2% (range: 4.8%–17.0%); the median intrabatch coefﬁ-
cient of variation for the cohort quality control samples was
9.9% (range: 3.8%–16.4%).
The main analyses described in this paper were conducted
by using clinically deﬁned cutpoints (4, 19, 20): <25
nmol/L, 25–<37.5 nmol/L, 37.5–<50 nmol/L, 50–<75
nmol/L, 75–<100 nmol/L, and  100 nmol/L. The referent
category chosen was 50–<75 nmol/L because this range
includes the mean level of the US population (62.91 nmol/L,
standard error of the mean, 0.81 for males; 61.54 nmol/L,
standard error of the mean, 0.85 for females) according to
2000–2004 National Health and Nutrition Examination Sur-
vey data (21).
In addition to the core VDPP variables, the following
additional variables were requested for inclusion in the kid-
ney cancer analyses: family history of renal cancer, history
of high blood pressure at blood draw, and history of diabetes
at blood draw. The Wald statistic, generated by using con-
ditional logistic regression, was used to test the signiﬁcance
of differences between the kidney cancer cases and controls
for selected variables, including median 25(OH)D concen-
trations. Variables in the VDPP data set that were 1) asso-
ciated with both 25(OH)D and kidney cancer or 2) identiﬁed
based on the literature as risk factors for kidney cancer, or
both, were included in the fully adjusted models; these vari-
ables were education, body mass index, height, smoking
status, current alcohol drinking, history of high blood pres-
sure; and history of diabetes. All of these variables were
treated as categorical in the model with the exception of
height, which was treated as a continuous variable. Data
on physical activity were also obtained because this variable
has been shown to be associated with both kidney cancer
and circulating 25(OH)D (22, 23); however, this variable
may be in the causal pathway and not a confounder. For this
reason, physical activity was not included in the fully
adjusted model.
Conditional logistic regression models adjusting for the
variables listed above were constructed to estimate the
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cancer by 25(OH)D concentration, examined by using the
6-category clinically deﬁned cutpoint variable. Trend tests
were conducted by assigning values of 1–6 to the respective
25(OH)D categories and treating the new variable as con-
tinuous in the model. Unconditional logistic regression anal-
yses using a 5-category 25(OH)D variable with the
categories of 75–<100 nmol/L and  100 nmol/L com-
bined adjusting for the matching factors and the other po-
tential confounders listed above were also conducted to
examine the associations between 25(OH)D and kidney
cancer in strata based on predeﬁned categories of sex,
season (winter/summer), age at blood collection, race, lat-
itude, length of follow-up, calcium intake/supplementa-
tion, body mass index, cigarette smoking, history of high
blood pressure, and history of diabetes. No differences in
the investigated association were observed in these strati-
ﬁed analyses; thus, with the exception of the sex- and sea-
son-speciﬁc analyses, the results of the stratiﬁed analyses
are not presented here.
Additionally, pooled analyses using cohort-, sex-, and
season-speciﬁc quartile cutpoints (using the 2-season vari-
able), based on the distribution of circulating 25(OH)D
among all controls from all VDPP cancer sites combined,
were also conducted. Both conditional and unconditional
models were run with the lowest fourth as the referent cat-
egory; the results were similar. Analyses to adjust for season
using the residual method were also conducted, as described
in Gallicchio et al. (18). Residual adjustment for season
takes into account the gradual nature of changes in concen-
trations of 25(OH)D over the year, which may be better than
adjusting for season. For the residual analyses, conditional
logistic regression models were run with the lowest fourth as
the referent category.
All analyses described above were conducted for all kid-
ney cancer cases (and matched controls) and then for renal
cell carcinoma cases (and matched controls) only. Analyses
were also conducted by excluding cases (and matched con-
trols) diagnosed within 2 years of blood draw. Because the
resulting estimates from these analyses were similar, only
the stratiﬁed results based on all cases (and matched con-
trols) are presented.
Finally, meta-analyses were conducted to examine the
overall and sex-speciﬁc associations of both low (<25
nmol/L) and high ( 75 nmol/L) concentrations of circulat-
ing 25(OH)D compared with the referent category of
50–<75 nmol/L with kidney cancer for all of the contribut-
ing study cohorts. Pooled multivariate log odds ratio esti-
mates adjusted for the covariates in the models described
above (e.g., education, body mass index, high blood pres-
sure) were obtained by using inverse-variance weights in
random-effects models. Statistical heterogeneity was as-
sessed by using the DerSimonian and Laird Q statistic
(24). Because of small numbers of cases and controls in
the Shanghai Women’s Health Study and the Shanghai
Men’s Health Study, data from these cohorts were combined
for the overall meta-analyses. In addition, because of small
numbers ( 1 case in the high or low 25(OH)D category),
not all cohorts contributed to all of the meta-analyses. Spe-
ciﬁcally, the New York University Women’s Health Study
dropped out of the overall and female-speciﬁc high versus
referent 25(OH)D concentration meta-analyses; CLUE, the
Cancer Prevention Study II Nutrition Cohort, and the Mul-
tiethnic Cohort Study dropped out of the female-speciﬁc
low versus referent 25(OH)D concentration meta-analyses;
and the Cancer Prevention Study II Nutrition Cohort, the
Multiethnic Cohort Study, and the Prostate, Lung, Colorec-
tal and Ovarian Cancer Screening Trial dropped out of the
female-speciﬁc high versus referent 25(OH)D concentration
meta-analyses. To explore the inﬂuence of each cohort on
the results, the meta-analyses described above were re-
peated by excluding one cohort at a time.
Table 1. Characteristics of Participants, by Cohort, in the Investigation of Kidney Cancer Within
the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Cohort No. of
Cases
No. of
Controls
Median Years From
Blood Collection to
Cancer Diagnosis
(Interquartile Range)
Median Circulating 25(OH)D,
nmol/L (Interquartile Range)
Cases Controls
ATBC 286 286 8.5 (4.6–12.4) 33.8 (22.7–47.5) 31.6 (21.5–47.5)
CLUE 102 102 10.9 (5.1–15.9) 62.8 (46.7–80.4) 63.7 (49.7–81.3)
CPS-II 58 58 2.4 (1.1–3.7) 65.5 (45.2–74.8) 59.0 (43.5–83.7)
MEC 64 64 2.2 (1.1–3.4) 48.9 (35.5–78.4) 53.3 (39.3–73.0)
NYU-WHS 35 35 10.8 (5.2–15.4) 37.8 (22.7–50.0) 39.7 (30.4–56.1)
PLCO 161 161 5.1 (2.4–6.8) 53.0 (40.4–64.5) 55.0 (43.0–68.5)
SMHS 32 32 2.2 (0.8–3.1) 39.5 (32.6–51.9) 38.5 (28.0–52.9)
SWHS 37 37 4.7 (3.1–7.3) 37.6 (28.4–42.0) 30.9 (23.5–41.9)
Total 775 775 5.5 (2.7–9.9) 44.4 (30.7–62.9) 45.4 (30.2–62.5)
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II,
Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NYU-WHS, New
York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D; PLCO, Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial; SMHS, Shanghai Men’s Health Study; SWHS,
Shanghai Women’s Health Study.
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software, versions 9.1.3 and 9.2 (SAS Institute, Inc.,
Cary, North Carolina). All meta-analyses were conducted
by using the R function MiMa (25) in R version 2.8.1
(The R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
Overall, the median follow-up time for cases (time from
blood draw to case diagnosis) was 5.5 years (interquartile
range: 2.7–9.9) (Table 1). Median circulating 25(OH)D for
the kidney cancer cases and controls was 44.4 nmol/L
Table 2. Selected Characteristics of Cases and Controls in the Investigation of Kidney Cancer Within the Cohort Consortium Vitamin D Pooling
Project of Rarer Cancers
Characteristic
Cases (N 5 775) Controls (N 5 775)
P Value
a
No. % Median (Interquartile
Range) No. % Median (Interquartile
Range)
Age at blood collection,
years
60 (54–66) 60 (54–66) Matched
Sex Matched
Male 577 74.5 577 74.5
Female 198 25.5 198 25.5
Race Matched
White 623 80.4 621 80.1
Black 26 3.4 29 3.7
Asian 83 10.7 83 10.7
Other 40 5.2 39 5.0
Missing 3 0.4 3 0.4
Education 0.39
Less than high school 179 23.1 202 26.1
Completed high school 153 19.7 129 16.6
Vocational school 148 19.1 134 17.3
Some college 160 20.6 165 21.3
College graduate 75 9.7 72 9.3
Graduate studies 54 7.0 65 8.4
Missing 6 0.8 8 1.0
Latitude,   0.31
<35 154 19.9 148 19.1
35–42 239 30.8 252 32.5
>42 382 49.3 375 48.4
Family history of any
cancer
0.18
Yes 270 34.8 278 35.9
No 277 35.7 310 40.0
Missing 228 29.4 187 24.1
Height, cm 172.7 (166.0–178.0) 172.0 (165.1–177.0) <0.01
Body mass index, kg/m
2 0.01
<25.0 251 32.4 296 38.2
25.0–29.9 316 40.8 299 38.6
 30.0 156 20.1 126 16.3
Missing 52 6.7 54 7.0
Cigarette smoking <0.01
Never 208 26.8 250 32.3
Former 193 24.9 173 22.3
Current 366 47.2 345 44.5
Missing 8 1.0 7 0.9
Table continues
50 Gallicchio et al.
Am J Epidemiol 2010;172:47–57(interquartile range: 30.7–62.9) and 45.4 nmol/L (interquar-
tile range: 30.2–62.5), respectively (P ¼ 0.71).
The distribution of selected characteristics of the cases
and controls is shown in Table 2. Approximately 75% of the
participants were male, the majority were white (80.4% of
cases and 80.1% of controls), and the median age at blood
collection of both cases and controls, overall, was 60 years.
For both males and females, cases were more likely than
Table 2. Continued
Characteristic
Cases (N 5 775) Controls (N 5 775)
P Value
a
No. % Median (Interquartile
Range) No. % Median (Interquartile
Range)
Current alcohol drinker 0.42
Yes 440 56.8 460 59.4
No 230 29.7 221 28.5
Missing 105 13.5 94 12.1
Physical activity,
intensity
0.04
Low/none 255 32.9 244 31.5
Light 247 31.9 234 30.2
Moderate 85 11.0 96 12.4
Vigorous 90 11.6 121 15.6
Missing 98 12.6 80 10.3
History of high blood
pressure
<0.01
Yes 267 34.5 206 26.6
No 495 63.9 566 73.0
Missing 13 1.7 3 0.4
History of diabetes 0.68
Yes 52 6.7 50 6.5
No 701 90.5 715 92.3
Missing 22 2.8 10 1.3
Supplement use
characteristics
Current supplement,
any
0.88
Yes 171 22.1 171 22.1
No 438 56.5 442 57.0
Missing 166 21.4 162 20.9
Current vitamin D
supplement
0.32
Yes 37 4.8 44 5.7
No 471 60.8 459 59.2
Missing 267 34.5 272 35.1
Current calcium
supplement
0.79
Yes 98 12.6 105 13.5
No 585 75.5 577 74.5
Missing 92 11.9 93 12.0
Dietary intake/day
Energy, kcal 2,137.2 (1,647.8–2,712.3) 2,161.5 (1,653.7–2,799.1) 0.32
Vitamin D, IU 169.6 (115.6–248.5) 169.9 (112.2–241.4) 0.48
Calcium, mg 912.3 (622.0–1,385.4) 1,003.9 (610.6–1,383.5) 0.35
Fish, g 25.4 (13.8–43.0) 24.2 (12.6–42.9) 0.09
Dairy, g 251.8 (66.8– 718.9) 262.8 (70.6–698.1) 0.93
a Wald test from conditional logistic regression, excluding subjects with missing data.
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males, but not females, cases were taller, had a higher mean
body mass index, were more likely to be categorized as
overweight or obese, and were more likely to report being
a current smoker compared with controls (data not shown).
There were no statistically signiﬁcant differences among
cases and controls with respect to dietary intake or supple-
ment use variables.
As shown in Table 3, 25(OH)D concentrations were not
signiﬁcantly associated with the risk of developing kidney
cancer for males and females combined (P-trend ¼ 0.76).
Adjustment for covariates that have been shown in previous
studies to be associated with kidney cancer, including body
mass index, height, smoking status, history of high blood
pressure, current alcohol drinking, and education, did not
signiﬁcantly change the results (P-trend ¼ 0.86). Similar
results for the unadjusted and adjusted conditional logistic
regression modeling were obtained when examining renal
cell carcinomas only (P-trend ¼ 0.67 for the multivariate-
adjusted model) and when limiting the sample to cases di-
agnosed more than 2 years after blood draw and their
matched controls (P-trend ¼ 0.95 for the multivariate-
adjusted model). After excluding subjects from the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study, who
constituted 36.9% of the sample, the multivariate-adjusted
odds ratios for the highest and lowest categories of
25(OH)D tended to be more inverse at both the high and
low extremes compared with the analysis including all co-
horts (<25 nmol/L odds ratio (OR) ¼ 0.75, 95% conﬁdence
interval (CI): 0.40, 1.41;  100 nmol/L OR ¼ 0.57, 95% CI:
0.27, 1.17; P-trend ¼ 0.32). Analyses using the pooled
cohort-, sex-, and season-speciﬁc quartile cutpoints, as well
as those using residual adjustment for season, showed no
increase or decrease in risk of kidney cancer or renal cell
carcinoma in the highest quartile compared with the lowest
quartile of circulating 25(OH)D (data not shown).
In the analyses stratiﬁed by sex (Table 4), low concentra-
tions of circulating 25(OH)D were not associated with kid-
ney cancer risk for either males (OR ¼ 1.04, 95% CI: 0.68,
1.58) or females (OR ¼ 0.66, 95% CI: 0.24, 1.77). High
25(OH)D concentrations ( 75 nmol/L) were associated
with a nonstatistically signiﬁcant increased risk of kidney
cancer for males (OR ¼ 1.52, 95% CI: 0.95, 2.41), even
after excluding cohort subjects from the Alpha-Tocopherol,
Beta-Carotene Cancer Prevention Study (OR ¼ 1.52, 95%
CI: 0.89, 2.59). In contrast, among females, high concentra-
tions of 25(OH)D were associated with a statistically signif-
icant decreased risk of kidney cancer (OR ¼ 0.31, 95% CI:
0.12, 0.85). Overall, there was no statistical evidence of
a sex–25(OH)D interaction (P ¼ 0.42). No differences in
Table 3. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Risk of Kidney Cancer Within the
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, Overall and for Renal Cell Carcinoma Subtype and Cases Diagnosed More Than
2 Years After Blood Draw
Circulating 25(OH)D, nmol/L
P Value <25 25–<37.5 37.5–<50 50–<75 75–<100 ‡100
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
All kidney cancers
No. of cases 119 164 173 219 80 20
No. of controls 136 152 144 240 75 28
Crude 0.97 0.68, 1.37 1.16 0.85, 1.58 1.30 0.97, 1.74 1.0 Referent 1.14 0.78, 1.67 0.77 0.40, 1.45 0.76
Multivariate
adjusted
a 0.94 0.64, 1.37 1.18 0.84, 1.67 1.18 0.85, 1.62 1.0 Referent 1.19 0.78, 1.83 0.92 0.44, 1.92 0.86
Renal cell
carcinomas
No. of cases 111 145 155 202 77 18
No. of controls 123 138 132 220 70 25
Crude 0.99 0.69, 1.42 1.12 0.81, 1.56 1.27 0.94, 1.73 1.0 Referent 1.18 0.80, 1.75 0.76 0.39, 1.51 0.84
Multivariate
adjusted
a 0.94 0.63, 1.39 1.13 0.78, 1.63 1.12 0.80, 1.58 1.0 Referent 1.24 0.79, 1.93 0.96 0.43, 2.14 0.67
All kidney cancers
diagnosed >2
years after
blood draw
No. of cases 106 129 146 185 51 16
No. of controls 119 124 118 194 56 22
Crude 0.95 0.65, 1.39 1.09 0.77, 1.54 1.30 0.94, 1.79 1.0 Referent 0.92 0.58, 1.44 0.71 0.34, 1.47 0.67
Multivariate
adjusted
a 0.91 0.61, 1.38 1.10 0.75, 1.63 1.15 0.80, 1.66 1.0 Referent 0.91 0.54, 1.52 0.79 0.33, 1.88 0.95
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Conditional models were adjusted for education, body mass index, height, smoking status, history of high blood pressure, history of diabetes,
and alcohol drinking.
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cancer were observed for individuals who had their blood
drawn in the winter season compared with individuals who
had their blood drawn in the summer season.
The associations with kidney cancer for both low (<37.5
nmol/L) and high ( 75 nmol/L) concentrations of circu-
lating 25(OH)D compared with the referent category of
50–<75 nmol/L in each of the contributing study popula-
tions are shown onFigure 1.Overall,the pooledodds ratios
for the high and low categories of 25(OH)D versus the
referent category were 1.01 (95% CI: 0.65, 1.58) and
1.12 (95% CI: 0.79, 1.59), respectively. The pooled odds
ratios for males and females for the high category of
25(OH)D versus the referent category were 1.33 (95%
CI: 0.80, 2.24) and 0.52 (95% CI: 0.06, 4.89), respectively.
The pooled odds ratios for males and females for the low-
est category of 25(OH)D versus the referent category were
1.07 (95% CI: 0.71, 1.61) and 0.73 (95% CI: 0.17, 3.22),
respectively. There was no evidence of statistical hetero-
geneity across studies in any of the meta-analyses (data not
shown). Results from analyses that excluded cohorts one at
a time showed no substantial changes in the pooled odds
ratios.
DISCUSSION
The ﬁndings from this large consortium-based prospec-
tive study do not support the hypothesis that circulating
25(OH)D concentrations are associated with the risk of
kidney cancer overall or the renal cell carcinoma subtype.
Although our data suggest a possible decrease in risk for
females associated with high 25(OH)D concentrations ( 75
nmol/L), the linear trend was not statistically signiﬁcant and
the number of cases in this category was small (n ¼ 14). The
overall null results we report for kidney cancer are similar to
the results examining circulating 25(OH)D in relation to the
other VDPP rarer cancer outcomes, including endometrial
cancer (26), ovarian cancer (27), upper gastrointestinal
cancer (28), and non-Hodgkin lymphoma (29). In contrast,
the data from VDPP indicate an increased risk of pancreatic
cancer associated with 25(OH)D concentrations of 100
nmol/L or more (30).
Despite the fact that the kidney is a major organ for
vitamin D metabolism and activity, few studies have been
conducted on vitamin D and kidney cancer. To our knowl-
edge, there are no prospective serum-based investigations,
and all published studies examined dietary intake of vitamin
D as a measure of vitamin D status. All but one of these
Table 4. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Risk of Kidney Cancer Within the
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, by Sex and Season
Strata
Circulating 25(OH)D, nmol/L
P Trend <25 25–<37.5 37.5–<50 50–<75 ‡75
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Males
No. of cases 98 117 123 153 86
No. of controls 113 108 102 179 75
Multivariate
adjusted
a 1.04 0.68, 1.58 1.33 0.88, 2.01 1.36 0.94, 1.99 1.0 Referent 1.52 0.95, 2.41 0.67
Females
No. of cases 21 47 50 66 14
No. of controls 23 44 42 61 29
Multivariate
adjusted
a 0.66 0.24, 1.77 0.84 0.41, 1.71 0.79 0.39, 1.60 1.0 Referent 0.31 0.12, 0.85 0.65
Winter
b
No. of cases 97 101 90 83 27
No. of controls 98 93 84 89 29
Multivariate
adjusted
c 1.14 0.71, 1.84 1.25 0.79, 1.96 1.18 0.75, 1.85 1.0 Referent 0.99 0.52, 1.90 0.49
Summer
b
No. of cases 22 63 83 136 73
No. of controls 38 59 60 151 74
Multivariate
adjusted
c 0.68 0.35, 1.31 1.09 0.66, 1.79 1.40 0.88, 2.21 1.0 Referent 1.26 0.78, 2.03 0.38
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Conditional models were adjusted for education, body mass index, height, smoking status, history of high blood pressure, history of diabetes,
and alcohol drinking.
b Winter was deﬁned as December–May and summer as June–November.
c Unconditional models were adjusted for date of blood draw, age at blood collection, race, sex, education, body mass index, height, smoking
status, history of high blood pressure, history of diabetes, and alcohol drinking.
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Figure 1. Forest plots for the meta-analysis of the association between circulating 25-hydroxyvitamin D (25(OH)D) and the risk of kidney cancer within the Cohort Consortium Vitamin D
Pooling Project of Rarer Cancers. Risk estimates, by cohort, for subjects with circulating 25(OH)D concentrations of A) <37.5 nmol/L and B)  75 nmol/L compared with the referent group (50–
<75 nmol/L). Odds ratios (ORs) and 95% conﬁdence intervals (CIs) were derived from conditional logistic regression models adjusted for education, body mass index, height, smoking status,
history of high blood pressure, history of diabetes, and alcohol drinking. The boxes show the odds ratios, the bars show the 95% conﬁdence intervals, and the size of each box is inversely
proportional to the variance of the log odds ratio estimate in each cohort. The overall estimates (diamonds) were derived from a meta-analysis using random-effects modeling. NYU-WHS data
are not included in the highest versus reference category forest plot (B) because there were zero cases of kidney cancer among cases in the highest category. ATBC, Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study; CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NYU-WHS, New York University Women’s Health Study; PLCO,
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SMHS/SWHS, Shanghai Men’s Health Study/Shanghai Women’s Health Study.
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7studies, however, reported ﬁndings consistent with our over-
all null result. For example, prospective cohort studies of
male smokers in Finland (the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study) and women in Iowa
(the Iowa Women’s Health Study) showed no statistically
signiﬁcant association between vitamin D intake and renal
cell carcinoma after adjustment for age (15) and other
potential confounders such as high blood pressure (17).
Furthermore, a case-control study conducted in Denmark
showed no association between the intake of individual
foods rich in vitamin D (i.e., ﬁsh and eggs) and renal cell
carcinoma risk (16), and a large case-control study con-
ducted in central and eastern Europe observed no statisti-
cally signiﬁcant increase or decrease in renal cell carcinoma
risk with total vitamin D intake (31). In contrast, one Italian
case-control study of 767 cases and 1,532 controls reported
a statistically signiﬁcant inverse association between dietary
vitamin D intake, based on a 78-item food frequency ques-
tionnaire, and the risk of renal cell carcinoma; however, this
ﬁnding was observed among only females (OR ¼ 0.60),
participants with a high body mass index ( 25 kg/m
2)
(OR ¼ 0.65), and never smokers (OR ¼ 0.61).
In general, studies, primarily ecologic, investigating the
association between cancer risk and sun exposure have re-
ported an inverse relation between kidney cancer incidence
and mortality with ultraviolet B light exposure (12, 13,
32–34). For example, Mohr et al. (12) examined the as-
sociation between ultraviolet B exposure and renal cancer
risk in 175 countries using latitude and solar ultraviolet B
irradiance. For both males and females, the highest renal
carcinoma risk rates were found in countries situated at
the highest latitudes. Furthermore, an occupational cohort
study exploring the relation between ultraviolet exposure
and cancer risk among Swedish male construction
workers found that participants exposed to the highest
level of occupational sunlight had a reduced kidney can-
cer risk (35). Additionally, a recent central and eastern
European case-control study reported inverse associations
between occupational ultraviolet exposure and renal cell
carcinoma risk that, after stratiﬁcation, were limited to
males residing in the highest latitudes (36). Similar in-
verse associations in case-control studies have been re-
ported between occupational sunlight exposures and other
cancers such as diffuse large B-cell lymphoma, follicular
lymphoma, and rectal and prostate cancer (refer, for ex-
ample, to Boffetta et al. (37), Slattery et al. (38), and John
et al. (39)).
A major strength of the present investigation is the in-
c l u s i o no fal a r g en u m b e ro fk i d n e yc a n c e rc a s e sf r o m
multiple cohort studies that incorporated a wide range of
vitamin D concentrations and latitudes. Furthermore,
since the study is prospective, with vitamin D status as-
sessed from blood samples collected before cancer diag-
nosis, the inﬂuence of reverse causality was minimized.
Moreover, circulating 25(OH)D concentrations were as-
sayed by a single laboratory to reduce interlaboratory var-
iation. Additionally, this measure of vitamin D exposure
represents an internal dose that includes the 2 major sour-
ces of vitamin D: sun exposure and intake. Finally, this
study collected data on a number of potential confounders
such as high blood pressure and body mass index that were
used in the analysis to allow for a more accurate estima-
tion of the association between 25(OH)D and kidney can-
cer risk.
Limitations of our study include measurement of only
a single blood sample; 25(OH)D measurements from mul-
tiple time points would have resulted in more precise
estimates of exposure. However, it should be noted that
data from several studies suggest that 25(OH)D concen-
trations are relatively stable when samples are collected
during the same season in different years. For example,
a study conducted in the New York University Women’s
Health Study found an intraclass correlation coefﬁcient
for circulating 25(OH)D of 0.78 (95% CI: 0.64, 0.88) in
30 healthy women who contributed 3 samples each at
yearly intervals (Anne Zeleniuch-Jacquotte, New York
University School of Medicine, personal communication,
2009). Other limitations include the possibility that the
etiologically relevant time period of exposure was missed
with the single blood sample and limited power to exam-
ine associations among subgroups with a small number of
cases.
In summary, the combined data from 8 prospective cohort
studies do not support the hypothesis that higher circulating
25(OH)D measured in prediagnostic blood specimens is
associated with a decreased risk of kidney cancer overall
or with renal cell carcinoma speciﬁcally.
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